DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
5.25
+0.03 (0.57%)
Aug 13, 2025, 10:00 AM - Market open
DiaMedica Therapeutics Employees
As of December 31, 2024, DiaMedica Therapeutics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,056,429
Market Cap
271.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | 3 | 18.75% |
| Dec 31, 2022 | 16 | 1 | 6.67% |
| Dec 31, 2021 | 15 | 4 | 36.36% |
| Dec 31, 2020 | 11 | 2 | 22.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DMAC News
- 17 hours ago - DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - Business Wire
- 7 days ago - DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer - Business Wire
- 7 days ago - DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 - Business Wire
- 20 days ago - DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement - Business Wire
- 23 days ago - DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline - Business Wire
- 27 days ago - DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - Business Wire
- 7 weeks ago - DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes - Business Wire
- 2 months ago - DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - Business Wire